RxDoctor Payments Data

Charli Souza

Family · Detroit, MINPI 1477193134

Payments from drug & device makers

$2,262in general payments, 2019–2025

Across 121 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$494
  • Bayer$223
  • Boehringer Ingelheim$206
  • Corcept Therapeutics$170
  • AbbVie$143
  • Lilly USA, LLC$138
  • plus $888 from 22 others

What the payments were for

  • Food & beverage$2,262100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,262 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$74,502
Medicare patients
152
Services billed
1,043

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$79,151
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$47,653
JardianceEmpagliflozin47$35,572
OzempicSemaglutide25$24,350
Tresiba Flextouch U-100Insulin Degludec17$17,803
EntrestoSacubitril/Valsartan17$16,593
XareltoRivaroxaban15$13,508
JanuviaSitagliptin Phosphate18$13,473
Breo ElliptaFluticasone/Vilanterol26$11,357
VascepaIcosapent Ethyl21$9,658
Icosapent Ethyl25$5,300
Albuterol Sulfate HfaAlbuterol Sulfate67$2,939
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen105$2,654
Omeprazole227$2,127
Levothyroxine Sodium221$2,064

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$79,15188 claims
GSKTrelegy Ellipta, Breo Ellipta$13$59,01097 claims
Boehringer IngelheimJardiance$206$35,57247 claims
Novo NordiskOzempic$494$24,35025 claims
Johnson & JohnsonXarelto$13$13,50815 claims
MerckJanuvia$14$13,47318 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$30$2,064221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,657 family providers in Michigan.

Other family in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →